The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.
An article from
China competition
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.
Published May 11, 2026
A GSK logo is seen on the side of an office building in Poznan, Poland.
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration
Global drugmakers eye more China biotech deals after record year
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition
Hims' sales miss as telehealth competition grows
Lilly, Gilead lead pharma’s M&A boom
How GSK is rebuilding its cancer business
A political contest in the U.K. could shake up drug pricing
